The effects of Cantharidin and Cantharidin derivates on tumour cells

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 4, 2009, Pages 392-396

  Liu, Dongwu ^a   Chen, Zhiwei ^a  

^a SHANDONG UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Cantharidin; Cantharidin derivates; Molecular mechanism; Tumour cell

Indexed keywords

ANTINEOPLASTIC AGENT; CAN 032; CAN 037; CANTHARIDIN; CANTHARIDIN DERIVATIVE; CARBOPLATIN; CISPLATIN; DEMETHYLCANTHARIDIN; DEMETHYLCANTHARIDIN INTEGRATED PLATINUM COMPLEX; OXALIPLATIN; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; SURVIVIN; UNCLASSIFIED DRUG; DRUG DERIVATIVE; PLATINUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; DRUG STRUCTURE; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; REVIEW; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; CANTHARIDIN; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MAP KINASE SIGNALING SYSTEM; ORGANOPLATINUM COMPOUNDS; PHOSPHOPROTEIN PHOSPHATASES; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 67649817034     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520610909040392     Document Type: Review

References (41)

1. Wang, G.S. Medical uses of mylabris in ancient China and recent studies. J. Ethnopharmacol., 1989, 26(2), 147-162.
2. Liu, X.H.; Blazsek, I.; Comisso, M.; Legras, S.; Marion, S.; Quittet, P.; Anjo, A.; Wang, G.S.; Misset, J.L. Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells. Eur. J. Cancer, 1995, 31A(6), 953-963.
3. Yi, S.N.; Wass, J.; Vincent, P.; Iland, H. Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro. Leuk. Res., 1991, 15(10), 883-886.
4. Efferth, T.; Davey, M.; Olbrich, A.; Rücker, G.; Gebhart, E.; Davey, R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol. Dis., 2002, 28(2), 160-168.
5. Tsauer, W.; Lin, J.G.; Lin, P.Y.; Hsu, F.L.; Chiang, H.C. The effects of cantharidin analogues on xanthine oxidase. Anticancer Res., 1997, 17(3C), 2095-2098.
6. Zhang, S. A study on antitumor chemotherapeutic agents: synthesis of N-cantharidine derivatives. Yao Xue Xue Bao, 1981, 16(10), 784-786.
7. Zhao, J.; Wu, H.W.; Chen, Y.J.; Tian, H.P.; Li, L.X.; Han, X.; Guo, J. Protein phosphatase 2A-negative regulation of the protective signaling pathway of Ca2+/CaM-dependent ERK activation in cerebral ischemia. J. Neurosci. Res., 2008, 86(12), 2733-2745.
8. Schweyer, S.; Bachem, A.; Bremmer, F.; Steinfelder, H.J.; Soruri, A.; Wagner, W.; Pottek, T.; Thelen, P.; Hopker, W.W.; Radzun, H.J.; Fayyazi, A. Expression and function of protein phosphatase PP2A in malignant testicular germ cell tumours. J. Pathol., 2007, 213(1), 72-81.
9. Sagawa, M.; Nakazato, T.; Uchida, H.; Ikeda, Y.; Kizaki, M. Cantharidin induces apoptosis of human multiple myeloma cells via inhibition of the JAK/STAT pathway. Cancer Sci, 2008, 99(9), 1820-1826.
10. Cohen, P.T.; Philp, A.; Vázquez-Martin, C. Protein phosphatase 4-from obscurity to vital functions. FEBS Lett., 2005, 579(15), 3278-3286.
11. Aoki, T.; Tsukinoki, K.; Karakida, K.; Ota, Y.; Otsuru, M.; Kaneko, A. Expression of cyclooxygenase-2, Bcl-2 and Ki-67 in pleomorphic adenoma with special reference to tumor proliferation and apoptosis. Oral. Oncol., 2004, 40(9), 954-959.
12. Qiu, Z.; Zhu, J.; Harms, J.S.; Friedrichsen, J.; Splitter, G.A. Bovine herpesvirus VP22 induces apoptosis in neuroblastoma cells by upregulating the expression ratio of Bax to Bcl-2. Hum. Gene Ther., 2005, 16(1), 101-108.
13. Zheng, X.L.; Sun, H.X.; Liu, X.L.; Chen, Y.X.; Qian, B.C. Astilbic acid induced COLO 205 cell apoptosis by regulating Bcl-2 and Bax expression and activating caspase-3. Acta Pharmacol. Sin., 2004, 25(8), 1090-1095.
14. Santini, D.; Tonini, G.; Vecchio, F.M.; Borzomati, D.; Vincenzi, B.; Valeri, S.; Antinori, A.; Castri, F.; Coppola, R.; Magistrelli, P.; Nuzzo, G.; Picciocchi, A. Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma. J. Clin. Pathol., 2005, 58(2), 159-165.
15. Bowen, J.M.; Gibson, R.J.; Keefe, D.M.; Cummins, A.G. Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology, 2005, 37(1), 56-62.
16. Rauh, R.; Kahl, S.; Boechzelt, H.; Bauer, R.; Kaina, B.; Efferth, T. Molecular biology of cantharidin in cancer cells. Chin. Med., 2007, 2, 8.
17. Zhang, W.D.; Zhao, H.R.; Yan, Y.; Wang, X.H.; Zong, Z.H.; Liu, Y. Apoptosis induced by cantharidin in human pulmonary carcinoma cells A549 and its molecular mechanisms. Zhonghua Zhong Liu Za Zhi, 2005, 27(6), 330-334.
18. Bonness, K.; Aragon, I.V.; Rutland, B.; Ofori-Acquah, S.; Dean, N.M.; Honkanen, R.E. Cantharidin-induced mitotic arrest is associated with the formation of aberrant mitotic spindles and lagging chromosomes resulting, in part, from the suppression of PP2Aalpha. Mol. Cancer Ther., 2006, 5(11), 2727-2736.
19. Koss, D.J.; Hindley, K.P.; Riedel, G.; Platt, B. Modulation of hippocampal calcium signalling and plasticity by serine/threonine protein phosphatases. J. Neurochem., 2007, 102(4), 1009-1023.
20. Efferth, T.; Rauh, R.; Kahl, S.; Tomicic, M.; Böchzelt, H.; Tome, M.E.; Briehl, M.M.; Bauer, R.; Kaina, B. Molecular modes of action of cantharidin in tumor cells. Biochem. Pharmacol., 2005, 69(5), 811-818.
21. Shen, Q.; Yao, Y.J.; Li, R.Y.; Ding, C.L.; Hou, L.C.; Sun, X.D. Cantharidin regulates intracellular ATP in G1/S-phase renal tubule epithelial cells. Di Yi Jun Yi Da Xue Xue Bao, 2004, 24(10), 1192-1196.
22. Williams, L.A.; Moller, W.; Merisor, E.; Kraus, W.; Rosner, H. In vitro anti-proliferation/cytotoxic activity of cantharidin (Spanish Fly) and related derivatives. West Indian Med. J., 2003, 52(1), 10-13.
23. Ho, Y.P.; To, K.K.; Au-Yeung, S.C.; Wang, X.; Lin, G.; Han, X. Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety. J. Med. Chem., 2001, 44(13), 2065-2068.
24. McCluskey, A.; Ackland, S.P.; Bowyer, M.C.; Baldwin, M.L.; Garner, J.; Walkom, C.C.; Sakoff, J.A. Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines. Bioorg. Chem., 2003, 31(1), 68-79.
25. Chen, Y.N.; Cheng, C.C.; Chen, J.C.; Tsauer, W.; Hsu, S.L. Norcantharidin-induced apoptosis is via the extracellular signal-regulated kinase and c-Jun-NH2-terminal kinase signaling pathways in human hepatoma HepG2 cells. Br. J. Pharmacol., 2003, 140(3), 461-470.
26. Peng, F.; Wei, Y.Q.; Tian, L.; Yang, L.; Zhao, X.; Lu, Y.; Mao, Y.Q.; Kan, B.; Lei, S.; Wang, G.S.; Jiang, Y.; Wang, Q.R.; Luo, F.; Zou, L.Q.; Liu, J.Y. Induction of apoptosis by norcantharidin in human colorectal carcinoma cell lines: involvement of the CD95 receptor/ligand. J. Cancer Res. Clin. Oncol., 2002, 128(4), 223-230.
27. Baba, Y.; Hirukawa, N.; Tanohira, N.; Sodeoka, M. Structurebased design of a highly selective catalytic site-directed inhibitor of Ser/Thr protein phosphatase 2B (calcineurin). J. Am. Chem. Soc., 2003, 125(32), 9740-9749.
28. Fan, Y.Z.; Fu, J.Y.; Zhao, Z.M.; Chen, C.Q. Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro. Hepatobiliary Pancreat Dis. Int., 2007, 6(1), 72-80.
29. Li, J.L.; Cai, Y.C.; Liu, X.H.; Xian, L.J. Norcantharidin inhibits DNA replication and induces apoptosis with the cleavage of initiation protein Cdc6 in HL-60 cells. Anticancer Drugs, 2006, 17(3), 307-314.
30. Chen, Y.J.; Kuo, C.D.; Tsai, Y.M.; Yu, C.C.; Wang, G.S.; Liao, H.F. Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells. Anticancer Drugs, 2008, 19(1), 55-64.
31. Kok, S.H.; Cheng, S.J.; Hong, C.Y.; Lee, J.J.; Lin, S.K.; Kuo, Y.S.; Chiang, C.P.; Kuo, M.Y. Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio. Cancer Lett., 2005, 217(1), 43-52.
32. Wong, E.; Giandomenico, C.M. Current status of platinum-based antitumor drugs. Chem. Rev., 1999, 99(9), 2451-2466.
33. Raymond, E.; Faivre, S.; Chaney, S.; Woynarowski, J.; Cvitkovic, E. Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther., 2002, 1(3), 227-235.
34. Di Francesco, A.M.; Ruggiero, A.; Riccardi, R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol. Life Sci., 2002, 59(11), 1914-1927.
35. Pang, S.K.; Yu, C.W.; Au-Yeung, S.C.; Ho, Y.P. DNA damage induced by novel demethylcantharidin-integrated platinum anticancer complexes. Biochem. Biophys. Res. Commun., 2007, 363(1), 235-240.
36. Yu, C.W.; Li, K.K.; Pang, S.K.; Au-Yeung, S.C.; Ho, Y.P. Anticancer activity of a series of platinum complexes integrating demethylcantharidin with isomers of 1,2-diaminocyclohexane. Bioorg. Med. Chem. Lett., 2006, 16(6), 1686-1691.
37. To, K.K.; Wang, X.; Yu, C.W.; Ho, Y.P.; Au-Yeung, S.C. Protein phosphatase 2A inhibition and circumvention of cisplatin cross-resistance by novel TCM-platinum anticancer agents containing demethylcantharidin. Bioorg. Med. Chem., 2004, 12(17), 4565-4573.
38. Kok, S.H.; Chui, C.H.; Lam, W.S.; Chen, J.; Lau, F.Y.; Cheng, G.Y.; Wong, R.S.; Lai, P.P.; Leung, T.W.; Tang, J.C.; Chan, A.S. Apoptotic activity of a novel synthetic cantharidin analogue on hepatoma cell lines. Int. J. Mol. Med., 2006, 17(5), 945-949.
39. Kok, S.H.; Chui, C.H.; Lam, W.S.; Chen, J.; Lau, F.Y.; Wong, R.S.; Cheng, G.Y.; Tang, W.K.; Teo, I.T.; Cheung, F.; Cheng, C.H.; Chan, A.S.; Tang, J.C. Apoptogenic activity of a synthetic cantharimide in leukaemia: implication on its structural activity relationship. Int. J. Mol. Med., 2006, 18(6), 1217-1221.
40. Cao, J.H.; Xu, B.; Li, M.; Wu, D.Z.; Huang, W.; Cui, J.R. Effect of norcantharidin's derivative Nd3 on proliferation of human ovarian cancer cell line SKOV3 and its possible mechanisms. Ai Zheng, 2007, 26(4), 361-366.
41. Yang, H.; Guo, W.; Xu, B.; Li, M.; Cui, J. Anticancer activity and mechanisms of norcantharidin-Nd3II on hepatoma. Anticancer Drugs, 2007, 18(10), 1133-1137.